Stock PSTV PLUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
1.8 USD 0.00% Intraday chart for Plus Therapeutics, Inc. +6.51% +2.85%
04-22 Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense MT
04-22 Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense CI

Business Summary

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

Number of employees: 20

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
0 100.0 % 5 100.0 % +2,093.30%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 5 100.0 % +2,093.30%

Managers

Managers TitleAgeSince
Marc Hedrick CEO
 Chief Executive Officer 61 30/09/02
Andrew Sims DFI
 Director of Finance/CFO 51 05/02/20
Pius Maliakal CTO
 Chief Tech/Sci/R&D Officer - 26/07/23
Norman LaFrance CTO
 Chief Tech/Sci/R&D Officer 76 07/12/21
Russ Havranek PRN
 Corporate Officer/Principal - 31/12/13

Members of the board

Members of the board TitleAgeSince
Marc Hedrick CEO
 Chief Executive Officer 61 30/09/02
Richard Hawkins CHM
 Chairman 75 30/11/07
Robert Lenk BRD
 Director/Board Member 75 29/02/20
J. Clowes BRD
 Director/Board Member 70 29/02/20
Greg Petersen BRD
 Director/Board Member 61 13/02/20
An van Es-Johansson BRD
 Director/Board Member 64 31/12/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,354,641 4,214,074 ( 96.77 %) 78,559 ( 1.804 %) 96.77 %

Shareholders

NameEquities%Valuation
Renaissance Technologies LLC
0.7717 %
33,000 0.7717 % 59 565 $
Vanguard Group, Inc. (Subfiler)
0.7610 %
32,541 0.7610 % 58 737 $
Geode Capital Management LLC
0.6207 %
26,543 0.6207 % 47 910 $
Robert Lenk
0.5884 %
25,160 0.5884 % 45 414 $
Greg Petersen
0.5652 %
24,167 0.5652 % 43 621 $
Citadel Securities GP LLC
0.3938 %
16,839 0.3938 % 30 394 $
Ground Swell Capital LLC
0.3345 %
14,303 0.3345 % 25 817 $
J. Clowes
0.2735 %
11,693 0.2735 % 21 106 $
UBS Securities LLC
0.2081 %
8,899 0.2081 % 16 063 $
BlackRock Institutional Trust Co. NA
0.1628 %
6,960 0.1628 % 12 563 $
NameEquities%Valuation
Marc Hedrick
3.731 %
35 3.731 % 63 $
Richard Hawkins
1.066 %
10 1.066 % 18 $
Tiago Girão
0.1066 %
1 0.1066 % 2 $

Company contact information

Plus Therapeutics, Inc.

4200 Marathon Boulevard Suite 200

78756, Austin

+737 255 7194

http://www.plustherapeutics.com
address Plus Therapeutics, Inc.(PSTV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Plus Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.8 USD
Average target price
16.5 USD
Spread / Average Target
+816.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PLUS THERAPEUTICS, INC. Stock Plus Therapeutics, Inc.
+2.85% 7.7M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PSTV Stock
  4. Company Plus Therapeutics, Inc.